Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Ruxolitinib Treatment Is Associated with Increased Incidence of Infections and Higher Risk of HSV/Vzv Recurrence in Patients with Myeloproliferative Neoplasm (MPN) Related Myelofibrosis (MF)

Nicolas Gauthier, MD, Juliette Soret-Dulphy, MD, Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Clemence Marcault, MD, Nathalie Parquet, MD, Jean-Marc Zini, Delphine Rea, MDPhD, Emmanuel Raffoux, MD, Bruno Cassinat, PharmD, PhD, Stephane Giraudier, MD PhD, Jean-Jacques Kiladjian, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-141260

Published: 2020

Journal Articles

Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission

Rafael Daltro De Oliveira, MD, Juliette Soret-Dulphy, MD, Lin-Pierre Zhao, MD, Clemence Marcault, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Nathalie Parquet, MD, Emmanuel Raffoux, MD, William Vainchenker, Christine Chomienne, MD PhD, Bruno Cassinat, PharmD, PhD, Lina Benajiba, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-141223

Published: 2020

Journal Articles

NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

Clemence Marcault, MD, Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Juliette Soret, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Blandine Roux, MSc, Nathalie Parquet, MD, Christine Dosquet, MD, Delphine Rea, MDPhD, Jean-Marc Zini, William Vainchenker, Emmanuel Raffoux, MD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-136177

Published: 2020

Journal Articles

SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Clemence Marcault, MD, Juliette Soret, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Blandine Roux, MSc, Nathalie Parquet, MD, Christine Dosquet, MD, Delphine Rea, MDPhD, Jean-Marc Zini, MD, William Vainchenker, Emmanuel Raffoux, MD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, MD PhD, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-141296

Published: 2020

Journal Articles

Topotecan Plus Cytarabine Is an Effective and Safe Regimen for Newly Diagnosed and Adverse ELN-Risk Acute Myeloid Leukemia Subset in Patients with Cardiac Comorbidities

Clemence Marcault, MD, Geoffroy Venton, Lauris Gastaud, MD, Lionel Mannone, MD, Jerome Rey, MD, Evelyne D'Incan, MD, Colombe Saillard, MD, Aude Charbonnier, MD, Sophie Raynaud, MD PhD, Norbert Vey, Thomas Cluzeau, MDPhD

Blood (2017) 130 (Supplement 1): 2615.

https://doi.org/10.1182/blood.V130.Suppl_1.2615.2615

Published: 2017

NARROW

Ruxolitinib Treatment Is Associated with Increased Incidence of Infections and Higher Risk of HSV/Vzv Recurrence in Patients with Myeloproliferative Neoplasm (MPN) Related Myelofibrosis (MF)

Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission

NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

Topotecan Plus Cytarabine Is an Effective and Safe Regimen for Newly Diagnosed and Adverse ELN-Risk Acute Myeloid Leukemia Subset in Patients with Cardiac Comorbidities

Email alerts

ASH Publications

American Society of Hematology

Ruxolitinib Treatment Is Associated with Increased Incidence of Infections and Higher Risk of HSV/Vzv Recurrence in Patients with Myeloproliferative Neoplasm (MPN) Related Myelofibrosis (MF)

Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission

NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

Topotecan Plus Cytarabine Is an Effective and Safe Regimen for Newly Diagnosed and Adverse ELN-Risk Acute Myeloid Leukemia Subset in Patients with Cardiac Comorbidities

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only